# Nautilus Biotechnology, Inc.: financial statements, quarterly

NAUT · Nasdaq · CIK 1808805 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/naut.md) · [Financials](/companies/naut/financials.md) · [Filings](/companies/naut/filings.md) · [Insiders](/companies/naut/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/naut/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001808805-26-000034.md) | [0.0](/filings/0001808805-26-000052.md) | not reported | not reported | [0.2](/filings/0001808805-26-000034.md) | [0.2](/filings/0001808805-26-000052.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001808805-26-000034.md) | [0.0](/filings/0001808805-26-000052.md) | not reported | not reported | [0.0](/filings/0001808805-26-000034.md) | [0.0](/filings/0001808805-26-000052.md) |
| Research and development | $m | [12.5 d](/filings/0001808805-25-000008.md) | [12.9](/filings/0001808805-25-000042.md) | [12.4](/filings/0001808805-25-000072.md) | [12.3](/filings/0001808805-25-000080.md) | [12.8 d](/filings/0001808805-26-000011.md) | [11.5](/filings/0001808805-26-000022.md) | [10.4](/filings/0001808805-26-000034.md) | [9.6](/filings/0001808805-26-000052.md) | [9.6 d](/filings/0001808805-26-000011.md) | [9.7](/filings/0001808805-26-000022.md) | [9.6](/filings/0001808805-26-000034.md) | [10.2](/filings/0001808805-26-000052.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | [7.3](/filings/0001808805-26-000022.md) | [6.7](/filings/0001808805-26-000034.md) | [5.9](/filings/0001808805-26-000052.md) | not reported | [6.4](/filings/0001808805-26-000022.md) | [6.3](/filings/0001808805-26-000034.md) | [6.8](/filings/0001808805-26-000052.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0 d](/filings/0001808805-25-000008.md) | [0.0](/filings/0001808805-25-000042.md) | [0.0](/filings/0001808805-25-000072.md) | [0.0](/filings/0001808805-25-000080.md) | [0.0 d](/filings/0001808805-26-000011.md) | [0.0](/filings/0001808805-26-000022.md) | [0.0](/filings/0001808805-26-000034.md) | [0.0](/filings/0001808805-26-000052.md) | [0.0 d](/filings/0001808805-26-000011.md) | [0.0](/filings/0001808805-26-000022.md) | [0.0](/filings/0001808805-26-000034.md) | [0.0](/filings/0001808805-26-000052.md) |
| Net income | $m | [(17.0) d](/filings/0001808805-25-000008.md) | [(18.7)](/filings/0001808805-25-000042.md) | [(18.0)](/filings/0001808805-25-000072.md) | [(16.4)](/filings/0001808805-25-000080.md) | [(17.6) d](/filings/0001808805-26-000011.md) | [(16.6)](/filings/0001808805-26-000022.md) | [(15.0)](/filings/0001808805-26-000034.md) | [(13.6)](/filings/0001808805-26-000052.md) | [(13.8) d](/filings/0001808805-26-000011.md) | [(14.7)](/filings/0001808805-26-000022.md) | [(14.5)](/filings/0001808805-26-000034.md) | [(15.6)](/filings/0001808805-26-000052.md) |
| Diluted EPS | $ per share | not reported | [(0.15)](/filings/0001808805-25-000042.md) | [(0.14)](/filings/0001808805-25-000072.md) | [(0.13)](/filings/0001808805-25-000080.md) | not reported | [(0.13)](/filings/0001808805-26-000022.md) | [(0.12)](/filings/0001808805-26-000034.md) | [(0.11)](/filings/0001808805-26-000052.md) | not reported | [(0.12)](/filings/0001808805-26-000022.md) | [(0.11)](/filings/0001808805-26-000034.md) | [(0.12)](/filings/0001808805-26-000052.md) |
| Basic EPS | $ per share | not reported | [(0.15)](/filings/0001808805-25-000042.md) | [(0.14)](/filings/0001808805-25-000072.md) | [(0.13)](/filings/0001808805-25-000080.md) | not reported | [(0.13)](/filings/0001808805-26-000022.md) | [(0.12)](/filings/0001808805-26-000034.md) | [(0.11)](/filings/0001808805-26-000052.md) | not reported | [(0.12)](/filings/0001808805-26-000022.md) | [(0.11)](/filings/0001808805-26-000034.md) | [(0.12)](/filings/0001808805-26-000052.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.4](/filings/0001808805-25-000008.md) | [25.7](/filings/0001808805-24-000041.md) | [24.9](/filings/0001808805-24-000058.md) | [4.4](/filings/0001808805-24-000072.md) | [27.6](/filings/0001808805-26-000011.md) | [33.2](/filings/0001808805-25-000042.md) | [34.5](/filings/0001808805-25-000072.md) | [23.9](/filings/0001808805-25-000080.md) | [12.4](/filings/0001808805-26-000052.md) | [14.6](/filings/0001808805-26-000022.md) | [13.2](/filings/0001808805-26-000034.md) | [10.5](/filings/0001808805-26-000052.md) |
| Current assets | $m | [177](/filings/0001808805-25-000008.md) | [185](/filings/0001808805-24-000041.md) | [171](/filings/0001808805-24-000058.md) | [144](/filings/0001808805-24-000072.md) | [133](/filings/0001808805-26-000011.md) | [142](/filings/0001808805-25-000042.md) | [151](/filings/0001808805-25-000072.md) | [134](/filings/0001808805-25-000080.md) | [106](/filings/0001808805-26-000052.md) | [98.8](/filings/0001808805-26-000022.md) | [87.6](/filings/0001808805-26-000034.md) | [90.2](/filings/0001808805-26-000052.md) |
| Total assets | $m | [306](/filings/0001808805-25-000008.md) | [289](/filings/0001808805-24-000041.md) | [273](/filings/0001808805-24-000058.md) | [260](/filings/0001808805-24-000072.md) | [243](/filings/0001808805-26-000011.md) | [228](/filings/0001808805-25-000042.md) | [213](/filings/0001808805-25-000072.md) | [201](/filings/0001808805-25-000080.md) | [191](/filings/0001808805-26-000052.md) | [178](/filings/0001808805-26-000022.md) | [164](/filings/0001808805-26-000034.md) | [149](/filings/0001808805-26-000052.md) |
| Current liabilities | $m | [9.1](/filings/0001808805-25-000008.md) | [9.2](/filings/0001808805-24-000041.md) | [8.7](/filings/0001808805-24-000058.md) | [8.7](/filings/0001808805-24-000072.md) | [7.6](/filings/0001808805-26-000011.md) | [8.2](/filings/0001808805-25-000042.md) | [8.1](/filings/0001808805-25-000072.md) | [9.0](/filings/0001808805-25-000080.md) | [8.0](/filings/0001808805-26-000052.md) | [8.3](/filings/0001808805-26-000022.md) | [8.6](/filings/0001808805-26-000034.md) | [9.8](/filings/0001808805-26-000052.md) |
| Total liabilities | $m | [40.2](/filings/0001808805-25-000008.md) | [39.2](/filings/0001808805-24-000041.md) | [37.5](/filings/0001808805-24-000058.md) | [36.3](/filings/0001808805-24-000072.md) | [34.0](/filings/0001808805-26-000011.md) | [33.3](/filings/0001808805-25-000042.md) | [32.1](/filings/0001808805-25-000072.md) | [31.8](/filings/0001808805-25-000080.md) | [34.1](/filings/0001808805-26-000052.md) | [33.4](/filings/0001808805-26-000022.md) | [32.5](/filings/0001808805-26-000034.md) | [32.4](/filings/0001808805-26-000052.md) |
| Shareholders' equity | $m | [265](/filings/0001808805-26-000011.md) | [249](/filings/0001808805-25-000072.md) | [235](/filings/0001808805-25-000080.md) | [223](/filings/0001808805-25-000080.md) | [209](/filings/0001808805-26-000052.md) | [194](/filings/0001808805-26-000034.md) | [181](/filings/0001808805-26-000052.md) | [169](/filings/0001808805-26-000052.md) | [157](/filings/0001808805-26-000052.md) | [144](/filings/0001808805-26-000034.md) | [131](/filings/0001808805-26-000052.md) | [117](/filings/0001808805-26-000052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.9) d](/filings/0001808805-25-000008.md) | [(16.3)](/filings/0001808805-25-000042.md) | [(15.5) d](/filings/0001808805-25-000072.md) | [(13.1) d](/filings/0001808805-25-000080.md) | [(14.3) d](/filings/0001808805-26-000011.md) | [(13.9)](/filings/0001808805-26-000022.md) | [(13.4) d](/filings/0001808805-26-000034.md) | [(11.0) d](/filings/0001808805-26-000052.md) | [(12.4) d](/filings/0001808805-26-000011.md) | [(13.1)](/filings/0001808805-26-000022.md) | [(13.7) d](/filings/0001808805-26-000034.md) | [(13.3) d](/filings/0001808805-26-000052.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001808805-25-000008.md) | [0.6](/filings/0001808805-25-000042.md) | [0.5 d](/filings/0001808805-25-000072.md) | [0.7 d](/filings/0001808805-25-000080.md) | [0.3 d](/filings/0001808805-26-000011.md) | [0.2](/filings/0001808805-26-000022.md) | [0.4 d](/filings/0001808805-26-000034.md) | [0.4 d](/filings/0001808805-26-000052.md) | [0.2 d](/filings/0001808805-26-000011.md) | [0.5](/filings/0001808805-26-000022.md) | [0.5 d](/filings/0001808805-26-000034.md) | [1.4 d](/filings/0001808805-26-000052.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [125](/filings/0001808805-24-000041.md) | [125](/filings/0001808805-24-000058.md) | [125](/filings/0001808805-24-000072.md) | [125](/filings/0001808805-25-000042.md) | [125](/filings/0001808805-25-000072.md) | [125](/filings/0001808805-25-000080.md) | [126](/filings/0001808805-26-000022.md) | [126](/filings/0001808805-26-000034.md) | [126](/filings/0001808805-26-000052.md) | [127](/filings/0001808805-26-000022.md) | [127](/filings/0001808805-26-000034.md) | [127](/filings/0001808805-26-000052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 127,372,425 at 2026-10-22, from the cover of the [10-Q filed 2026-10-27](/filings/0001808805-26-000052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 27, 2026, 07:43 ET. No prices; not investment advice.